Publications by authors named "H Ibata"
Aberrant immune responses to viral pathogens contribute to pathogenesis, but our understanding of pathological immune responses caused by viruses within the human virome, especially at a population scale, remains limited. We analyzed whole-genome sequencing datasets of 6,321 Japanese individuals, including patients with autoimmune diseases (psoriasis vulgaris, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pulmonary alveolar proteinosis (PAP) or multiple sclerosis) and coronavirus disease 2019 (COVID-19), or healthy controls. We systematically quantified two constituents of the blood DNA virome, endogenous HHV-6 (eHHV-6) and anellovirus.
View Article and Find Full Text PDFArticle Synopsis
- A 54-year-old woman with Stage IIIb squamous cell carcinoma initially underwent chemoradiotherapy but faced cancer relapse two years later, leading to treatment with nivolumab, which was stopped due to drug-induced pneumonitis.
- After several unsuccessful treatments, including prednisolone and multiple cytotoxic agents, the patient received a combination therapy of cisplatin, gemcitabine, and necitumumab, followed by palliative radiation for lymph node enlargement.
- Remarkably, a treatment with atezolizumab resulted in significant tumor regression, suggesting earlier treatments may have influenced PD-L1 expression, highlighting the need for more research into treatment history's impact on therapy effectiveness in squamous cell carcinoma.
Background: Immune checkpoint inhibitors have recently become the standard of care in the first-line treatment of extensive-stage small cell lung cancer. Although immune-related adverse events have been reported to influence prognosis in non-small cell lung cancer patients, few studies have investigated the prognostic value of immune-related adverse events in small cell lung cancer patients. In this study, we evaluated the prognosis of patients who developed immune-related adverse events after first-line treatment with immune checkpoint inhibitor-based chemotherapy for extensive-stage small cell lung cancer.
View Article and Find Full Text PDFBackground: Although the loading dose (LD) of vancomycin (VCM) contributes to its efficacy, it may not be conducted adequately. Herein, the objective was to evaluate the effect of LD on patient prognosis using therapeutic drug monitoring by pharmacists and elucidate the impact of an antimicrobial stewardship program (ASP)-driven educational intervention on the LD implementation rate and patient prognosis.
Materials And Methods: First, a retrospective cohort study was conducted involving 121 adult patients administered with VCM and compared with 28-day mortality in LD and non-LD groups.
Article Synopsis
- Epidermal growth factor receptor (EGFR)-mutated squamous cell carcinoma (SCC) is rare compared to adenocarcinoma, and the effectiveness of osimertinib, a treatment known to work for adenocarcinoma, is uncertain for SCC.
- An 83-year-old male with EGFR exon19 deletion SCC treated with osimertinib experienced disease progression after 18 days, leading to his death three weeks later.
- Autopsy and next-generation sequencing indicated the presence of other genetic mutations (TP53 R158L, CDK6, and KRAS amplifications), suggesting these could explain osimertinib's failure in his case.